Structure-guided design of protease-resistant, lipopeptide inhibitors of SARS-CoV-2
SARS-CoV-2 蛋白酶抗性脂肽抑制剂的结构指导设计
基本信息
- 批准号:10679139
- 负责人:
- 金额:$ 6.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-01 至 2026-02-28
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVAddressAmino Acid SubstitutionAmino AcidsAnimal ModelAntiviral AgentsBiodistributionBiological AssayBiological AvailabilityC-terminalCOVID-19COVID-19 therapeuticsCell membraneCellsCessation of lifeChemicalsCholesterolCircular DichroismCollaborationsCoronavirusCrystallizationCrystallographyDataDevelopmentDoseDrug KineticsEconomicsEngineeringEtiologyExhibitsFluorescence PolarizationFoundationsGoalsHIVHalf-LifeHybridsIn VitroInfectionLearningLengthMediatingMembrane FusionMembrane ProteinsMiddle East Respiratory SyndromeModificationMolecularMolecular ConformationN-terminalPara-Influenza Virus Type 3PathogenesisPeptide HydrolasesPeptidesPositioning AttributePredispositionProductivityPropertyProphylactic treatmentProtein EngineeringProteinsProteolysisResearchResearch PersonnelResistanceResolutionSARS coronavirusSARS-CoV-2 infectionSARS-CoV-2 inhibitorSARS-CoV-2 variantSideSiteStructureSurfaceTechniquesTherapeutic AgentsTreatment EfficacyUniversitiesVaccinesVariantVertebral columnViralViral PhysiologyVirusVirus DiseasesVirus InhibitorsVulnerable PopulationsWisconsinWorkX ray diffraction analysisX-Ray Crystallographyanalogcareercoronavirus diseasedesignexperienceimprovedin vivoinhibitorinsightinterdisciplinary approachmimicrynovelnovel strategiesnovel therapeuticspandemic diseaseprotein expressionviral entry inhibitorvirology
项目摘要
PROJECT SUMMARY
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), the etiological agent of coronavirus
disease (COVID-19), has spurred an unprecedented global pandemic. Infection surges necessitate new
therapeutic agents that are effective against a rapidly changing virus. Antivirals that inhibit viral entry into host
cells have proven effective against other viruses with similar mechanisms of pathogenesis.
The long-term objective of this highly collaborative proposed research is to develop potent peptides
inhibitors of SARS-CoV-2 infection that operate by blocking structural rearrangements of the spike protein
required for viral entry into host cells. For SARS-CoV-2 infection to occur, the viral surface spike (S) protein, a
homotrimer, rearranges to form an energetically favored postfusion state. In this postfusion conformation, two
helical domains, the N-terminal (HRN) and C-terminal (HRC) heptad repeats, associate to form a 6-helix bundle
(6HB). Peptides derived from the HRC can inhibit formation of the 6HB, and thus SARS-CoV-2 infection.
However, conventional peptides, composed entirely of α-amino acid residues, are highly susceptible to
proteolytic degradation, which necessitates frequent and high dosing. The Gellman lab, in collaboration with
virologists Prof. Anne Moscona and Prof. Matteo Porotto at Columbia University, has demonstrated that site-
selective incorporation of backbone modifications, in combination with cholesterol conjugation, can decrease
proteolytic sensitivity while maintaining high antiviral potency. Our team recently found that such lipopeptides
can inhibit SARS-CoV-2 infection in biological assays and animal models, and that these inhibitors are effective
against SARS-CoV-2 variants, SARS-CoV-1 and MERS. Building on this foundation, my proposed project seeks
to develop lipopeptides containing backbone modifications that display high antiviral potency and resist
proteolysis. Aim 1 will produce potent inhibitors of SARS-CoV-2 (and other coronaviruses) that contain backbone
modifications and resist proteolysis. Aim 2 will evaluate the stability of 6HB formation between inhibitor
candidates and the native SARS-CoV-2 HRN. Aim 3 will elucidate critical structural interactions between the
HRC mimics and the native HRN.
My hypothesis is that site-selective incorporation of backbone modifications into HRC-based designs will
increase both antiviral activity and half-life in vivo, improving therapeutic efficacy. The proposed research, which
will be conducted under the guidance of Prof. Sam Gellman at the University of Wisconsin, will provide me with
experience in macromolecular X-ray crystallography, molecular design, protein engineering & expression, and
virology. Through structure-guided engineering and sophisticated and multi-pronged assay
implementation, these efforts could generate effective pan-variant therapeutics for COVID-19.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ariel Jade Kuhn其他文献
Ariel Jade Kuhn的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ariel Jade Kuhn', 18)}}的其他基金
Elucidating the biophysical and biological properties of the p3 fragment in Alzheimer's Disease
阐明阿尔茨海默病中 p3 片段的生物物理和生物学特性
- 批准号:
10065425 - 财政年份:2019
- 资助金额:
$ 6.87万 - 项目类别:
Elucidating the biophysical and biological properties of the p3 fragment in Alzheimer's Disease
阐明阿尔茨海默病中 p3 片段的生物物理和生物学特性
- 批准号:
10228755 - 财政年份:2019
- 资助金额:
$ 6.87万 - 项目类别:
Elucidating the biophysical and biological properties of the p3 fragment in Alzheimer's Disease
阐明阿尔茨海默病中 p3 片段的生物物理和生物学特性
- 批准号:
9910051 - 财政年份:2019
- 资助金额:
$ 6.87万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 6.87万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 6.87万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 6.87万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 6.87万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 6.87万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 6.87万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 6.87万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 6.87万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 6.87万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 6.87万 - 项目类别:
Research Grant